. Author manuscript; available in PMC: 2021 Feb 1.

Published in final edited form as: Leuk Lymphoma. 2019 Oct 16;61(2):309–317. doi: 10.1080/10428194.2019.1672052

Table 3.

Treatment-related adverse events at the MTD (n=18, highest grade per patient)

	Cycle 1		All Cycles
Adverse event, n (%)	Grade 3	Grade 4	Grade 3	Grade 4

Any AE
Blood and lymphatic system disorders
Anemia	2 (11%)	0 (0%)	3 (17%)	0 (0%)
Gastrointestinal disorders
Diarrhea	1 (6%)	0 (0%)	2 (11%)	0 (0%)
Gastric ulcer/pyloric stenosis/vomiting	0 (0%)	0 (0%)	1 (6%)	0 (0%)
Infections
Lung infection	1 (6%)	0 (0%)	2 (11%)	0 (0%)
Investigations
Neutrophil count decreased	0 (0%)	1 (6%)	2 (11%)	2 (11%)
Platelet count decreased	2 (11%)	0 (0%)	2 (11%)	0 (0%)
White blood cell decreased	1 (6%)	1 (6%)	2 (11%)	1 (6%)
Metabolism and nutrition disorders
Hypokalemia	1 (6%)	0 (0%)	1 (6%)	0 (0%)
Hypophosphatemia	2 (11%)	0 (0%)	2 (11%)	0 (0%)
Vascular disorders
Thromboembolic event	0 (0%)	0 (0%)	1 (6%)	0 (0%)